Boehringer Ingelheim Company Profile

✉ Email this page to a colleague

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are seventy US patents protecting BOEHRINGER INGELHEIM drugs.

There are one thousand eight hundred and twenty-six patent family members on BOEHRINGER INGELHEIM drugs in sixty-three countries and two hundred and seventeen supplementary protection certificates in nineteen countries.

Summary for Boehringer Ingelheim

International Patents:	1826
US Patents:	70
Tradenames:	37
Ingredients:	29
NDAs:	48
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	9,155,705*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	AB	RX	Yes	Yes	9,155,705*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-003	Jun 21, 2021		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Boehringer Ingelheim	SYNJARDY	empagliflozin; metformin hydrochloride	TABLET;ORAL	206111-002	Aug 26, 2015		RX	Yes	No	7,579,449*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	CAPSULE;ORAL	022512-003	Nov 20, 2015	AB	RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	11,911,388	⤷ Try a Trial				⤷ Try a Trial
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Boehringer Ingelheim

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	7,246,615*PED	⤷ Try a Trial
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-001	Nov 10, 1998	5,591,762	⤷ Try a Trial
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	6,890,898	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	6,846,413	⤷ Try a Trial
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	6,453,795*PED	⤷ Try a Trial
Boehringer Ingelheim	VIRAMUNE	nevirapine	SUSPENSION;ORAL	020933-001	Sep 11, 1998	5,366,972*PED	⤷ Try a Trial
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	8,119,648	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	400 mg	➤ Subscribe	2013-06-21
➤ Subscribe	Tablets	10 mg/5 mg and 25 mg/5 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg	➤ Subscribe	2015-05-04
➤ Subscribe	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg	➤ Subscribe	2008-12-31
➤ Subscribe	Extended-release Capsules	25 mg and 200 mg	➤ Subscribe	2007-02-01
➤ Subscribe	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg	➤ Subscribe	2005-06-24
➤ Subscribe	Capsules	eq. to 75 mg base and 150 mg base	➤ Subscribe	2014-10-20
➤ Subscribe	Tablets	0.75 mg	➤ Subscribe	2008-07-31
➤ Subscribe	Inhalation Powder Capsules	18 mcg	➤ Subscribe	2018-05-11
➤ Subscribe	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg	➤ Subscribe	2010-06-01
➤ Subscribe	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	20 mg, 30 mg and 40 mg	➤ Subscribe	2017-07-12
➤ Subscribe	Tablets	10 mg and 25 mg	➤ Subscribe	2018-08-01
➤ Subscribe	Tablets	20 mg, 40 mg and 80 mg	➤ Subscribe	2006-12-26
➤ Subscribe	Tablets	80 mg/25 mg	➤ Subscribe	2009-02-27
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	0.25 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Capsules	eq. to 110 mg base	➤ Subscribe	2015-12-15
➤ Subscribe	Oral Suspension	7.5 mg/5 mL	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg	➤ Subscribe	2018-03-28
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2015-05-04
➤ Subscribe	Extended-release Tablets	2.25 mg and 3.75 mg	➤ Subscribe	2011-07-26

International Patents for Boehringer Ingelheim Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	036618	⤷ Try a Trial
Taiwan	201011027	⤷ Try a Trial
Austria	406162	⤷ Try a Trial
Montenegro	00797	⤷ Try a Trial
Belgium	2015C038	⤷ Try a Trial
Hong Kong	1213498	⤷ Try a Trial
Germany	102008014025	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1224170	428	Finland	⤷ Try a Trial
2525812	1790034-1	Sweden	⤷ Try a Trial	PRODUCT NAME: IDARUCIZUMAB GODKAENNANDE EU/1/15/1056
1532149	92128	Luxembourg	⤷ Try a Trial	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
0503785	C300375	Netherlands	⤷ Try a Trial	PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
1562603	21/2014	Austria	⤷ Try a Trial	PRODUCT NAME: OLODATEROL, DESSEN SAEUREHAELTIGEN SALZE MIT PHARMAKOLOGISCH VERTRAEGLICHEN SAEUREN, IM BESONDEREN OLODATEROL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 135232 20131125; FIRST REGISTRATION: MT MA211/00401 20130918
1485094	54/2012	Austria	⤷ Try a Trial	PRODUCT NAME: DABIGATRANETEXILAT UND SEINE SALZE, INSBESONDERE DABIGATRANETEXILATMESILAT; REGISTRATION NO/DATE: EU/1/08/442/001 - EU1/08/442/008 20080318
1730131	PA2014035,C1730131	Lithuania	⤷ Try a Trial	PRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Boehringer Ingelheim

Summary for Boehringer Ingelheim

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing